U.S. Stem Cell Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 15

Employees

  • Stock Symbol
  • USRM

Stock Symbol

  • Investments
  • 1

U.S. Stem Cell General Information

Description

US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

Contact Information

Formerly Known As
Bioheart
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1560 Sawgrass Corporate Parkway
  • 4th Floor
  • Sunrise, FL 33323
  • United States
+1 (954)
Primary Industry
Biotechnology
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 1560 Sawgrass Corporate Parkway
  • 4th Floor
  • Sunrise, FL 33323
  • United States
+1 (954)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

U.S. Stem Cell Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
415K

U.S. Stem Cell Financials Summary

As of 31-Dec-2022, U.S. Stem Cell has a trailing 12-month revenue of $82K.

In Thousands,
USD
TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 11,769 11,769 10,713 11,164
Revenue 82 82 201 277
EBITDA (2,168) (2,168) (2,287) (2,402)
Net Income (2,858) (2,858) (3,287) (2,890)
Total Assets 68 68 51 88
Total Debt 8,947 8,947 8,016 7,485
Public Fundamental Data provided by Morningstar, Inc. disclaimer

U.S. Stem Cell Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore U.S. Stem Cell‘s full profile, request access.

Request a free trial

U.S. Stem Cell Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for th
Biotechnology
Sunrise, FL
15 As of 2025

Mont-Saint-Guibert, Belgium
 

Galway, Ireland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

U.S. Stem Cell Competitors (26)

One of U.S. Stem Cell’s 26 competitors is NOVADIP, a Venture Capital-Backed company based in Mont-Saint-Guibert, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NOVADIP Venture Capital-Backed Mont-Saint-Guibert, Belgium
Orbsen Therapeutics Formerly PE-Backed Galway, Ireland
BioCardia Formerly VC-backed Sunnyvale, CA
Mesoblast Corporation Melbourne, Australia
Regenerative Medical Solutions Venture Capital-Backed Madison, WI
You’re viewing 5 of 26 competitors. Get the full list »

U.S. Stem Cell Patents

U.S. Stem Cell Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20050171578-A1 Method of enhancing myogenesis by electrical stimulation Active 13-Jun-2001
US-7483749-B2 Method of enhancing myogenesis by electrical stimulation Inactive 13-Jun-2001
US-7341062-B2 Method of providing a dynamic cellular cardiac support Inactive 12-Mar-2001
AU-2001255850-A1 Catheter assembly for treating ischemic tissue Inactive 14-Dec-2000
AU-2001259073-A1 Catheter assembly for treating ischemic tissue Inactive 14-Dec-2000 A61M25/04
To view U.S. Stem Cell’s complete patent history, request access »

U.S. Stem Cell Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

U.S. Stem Cell Acquisitions (1)

U.S. Stem Cell’s most recent deal was a Merger/Acquisition with Pavillion Scientific. The deal was made on 03-Jun-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pavillion Scientific 03-Jun-2015 Merger/Acquisition Other Devices and Supplies
To view U.S. Stem Cell’s complete acquisitions history, request access »

U.S. Stem Cell ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Services

Subindustry

Rank

Percentile

To view U.S. Stem Cell’s complete esg history, request access »

U.S. Stem Cell FAQs

  • When was U.S. Stem Cell founded?

    U.S. Stem Cell was founded in 1999.

  • Where is U.S. Stem Cell headquartered?

    U.S. Stem Cell is headquartered in Sunrise, FL.

  • What is the size of U.S. Stem Cell?

    U.S. Stem Cell has 15 total employees.

  • What industry is U.S. Stem Cell in?

    U.S. Stem Cell’s primary industry is Biotechnology.

  • Is U.S. Stem Cell a private or public company?

    U.S. Stem Cell is a Public company.

  • What is U.S. Stem Cell’s stock symbol?

    The ticker symbol for U.S. Stem Cell is USRM.

  • What is U.S. Stem Cell’s current revenue?

    The trailing twelve month revenue for U.S. Stem Cell is $82K.

  • Who are U.S. Stem Cell’s competitors?

    NOVADIP, Orbsen Therapeutics, BioCardia, Mesoblast, and Regenerative Medical Solutions are some of the 26 competitors of U.S. Stem Cell.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process